What Do Analysts Think About Gilead Sciences (GILD)?

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a strong large-cap value stock with a maintained Buy rating and a price target of $143.00 by Morgan Stanley analyst Terence Flynn [1] - The positive outlook for Gilead is supported by a recent recommendation from the US CDC for its product Yeztugo for HIV pre-exposure prophylaxis (PrEP) [2] - JPMorgan analyst Chris Schott has increased the price target for Gilead from $135 to $145 while maintaining an Overweight rating, indicating confidence in the company's growth potential [3] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19 [3] - The company's drug portfolio addresses medical areas with unmet needs and includes products such as AmBisome, Atripla, Biktarvy, Cayston, and Complera [4] - Gilead operates in over 35 countries, highlighting its global presence and market reach [4]